Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations

被引:65
作者
Gertz, Michael [1 ]
Kilford, Peter J. [1 ]
Houston, J. Brian [1 ]
Galetin, Aleksandra [1 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England
关键词
D O I
10.1124/dmd.107.018713
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two predictive tools have been proposed by Austin et al. (Drug Metab Dispos 30: 1497-1503, 2002) and Hallifax and Houston (Drug Metab Dispos 34: 724-726, 2006) to estimate the fraction unbound in the incubation (fu(inc)). The current study was undertaken to elucidate the relative utility of these prediction tools over a range of drug lipophilicity and microsomal protein concentration. The fu(inc) data set (n = 127) comprised 35 drugs determined experimentally in this study and 92 collated from Austin and Hallifax data. The observed fu(inc) values at three microsomal concentrations were compared with the estimates obtained using the Austin and Hallifax equations. In addition, the impact of variability in the logP on the fu(inc) predictions was assessed. The current analysis highlights the importance of accurate estimation of lipophilicity for the prediction of the fu(inc), regardless of the prediction equation used. Both equations represent useful tools for estimation of fu(inc) for low lipophilicity drugs (logP/D = 0-3), especially at low microsomal protein concentration. However, the accuracy of fu(inc) predictions of highly lipophilic drugs was poor for both equations, implying that fu(inc) should be experimentally confirmed for drugs with logP/D >= 3, unless the microsomal protein concentration is as low as 0.1 mg/ml, in which case a cutoff of logP/D >= 5 can be applied. A significant difference in the predictions by the two proposed tools was observed in the area of intermediate lipophilicity (logP/D = 2.5-5), where the Hallifax equation provided more accurate fu(inc) predictions on average, irrespective of the microsomal protein concentration investigated.
引用
收藏
页码:535 / 542
页数:8
相关论文
共 27 条
[1]   The binding of drugs to hepatocytes and its relationship to physicochemical properties [J].
Austin, RP ;
Barton, P ;
Mohmed, S ;
Riley, RJ .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (03) :419-425
[2]   The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties [J].
Austin, RP ;
Barton, P ;
Cockroft, SL ;
Wenlock, MC ;
Riley, RJ .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) :1497-1503
[3]   Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding [J].
Banker, MJ ;
Clark, TH ;
Williams, JA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (05) :967-974
[4]   The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, RS ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :815-832
[5]   Prediction of in vivo drug-drug interactions from in vitro data -: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4 [J].
Brown, Hayley S. ;
Galetin, Aleksandra ;
Hallifax, David ;
Houston, J. Brian .
CLINICAL PHARMACOKINETICS, 2006, 45 (10) :1035-1050
[6]   Prediction of time-dependent CYP3A4 drug-drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition [J].
Galetin, A ;
Burt, H ;
Gibbons, L ;
Houston, JB .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (01) :166-175
[7]   CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions [J].
Galetin, A ;
Ito, K ;
Hallifax, D ;
Houston, JB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (01) :180-190
[8]   Intestinal and hepatic metabolic activity of five cytochrome p450 enzymes: Impact on prediction of first-pass metabolism [J].
Galetin, Aleksandra ;
Houston, J. Brian .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (03) :1220-1229
[9]   A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation [J].
Ghanbari, F ;
Rowland-Yeo, K ;
Bloomer, JC ;
Clarke, SE ;
Lennard, MS ;
Tucker, GT ;
Rostami-Hodjegan, A .
CURRENT DRUG METABOLISM, 2006, 7 (03) :315-334
[10]   The impact of in vitro binding on in vitro -: In vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions [J].
Grime, K ;
Riley, RJ .
CURRENT DRUG METABOLISM, 2006, 7 (03) :251-264